BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER OCTOBER 2014)

Development and Optimization of Gliclazide Sublingual Tablets by Using Co-Processed Excipient to Treat Type II Diabetes

M.Kiran Babu, Sujatha Kumari.M, Rehana Sulthana, Srinivas.M, Ch.Prasanthi

Introduction: Diabetes mellitus (DM) is a metabolous distract resulting from a disturbance in insulin secretion, insulin action, or both. Diabetes is a chronic disease that happens either when the pancreas does not produce adequate insulin or when the body cannot effectively make use of insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or conjured up blood sugar, is a common effect of ungoverned diabetes and over time leads to severe damage to many of the body's systems, especially the nerves and blood vessels. Gliclazide is a sulfonylurea derivative chemically N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4 methyl benzene sulfonamide used as an oral hypoglycemic agent. Its classification has been uncertain as literature uses it as both a first-generation and second-generation sulfonylurea. It is marketed as Diamicron and Dianorm in India. Gliclazide energizes insulin secretion from pancreatic β-cells, reduces hepatic gluconeogenesis, and turns down blood glucose concentrations. It also inhibits platelet aggregation at therapeutic doses1. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.